STOCK TITAN
  1. Home
  2. News
  3. VECT

VectivBio to Present at the 2022 Jefferies London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will be presenting at the Jefferies London Healthcare Conference on Thursday, November 17, 2022. A live webcast can be accessed through the link below.

Jefferies London Healthcare Conference
Date: Thursday, November 17, 2022
Presentation Time: 8:35 a.m. GMT / 3:35 a.m. ET
Webcast: https://wsw.com/webcast/jeff255/vect/1857438

An archived webcast of the presentation can be accessed through the Events and Presentations section of VectivBio’s website at www.vectivbio.com.

About VectivBio AG

VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Lead product candidate apraglutide is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD).

VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs). CoMET leverages innovative chemistry, based on a proprietary stabilized pantetheine backbone, to restore fundamental cellular metabolism in pediatric populations with IMDs characterized by a deficit of energy metabolism caused by the depletion of functional Coenzyme A (“CoA”). Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidemias.

VectivBio Contact:
Patrick Malloy
VectivBio SVP, Investor Relations and Strategic Communications
Patrick.malloy@vectivbio.com


Stock VECT logo
VECT

NASDAQ:VECT

VECT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

VECT Latest News

Jun 29, 2023
Alentis Therapeutics Appoints Luca Santarelli as Chairperson
Jun 29, 2023
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
Jun 26, 2023
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
Jun 16, 2023
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
May 22, 2023
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

VECT Stock Data

1.06B
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link

About VECT

vectivbio ag is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. vectivbio was formed in 2019 as a spinout from therachon, a biotechnology company acquired by pfizer, inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. the company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in r&d, commercialization and business development for innovative products targeting orphan conditions with major unmet medical need. the company is drawing on the expertise of its founders as it continues to build a portfolio of rare disease medicines while advancing its lead program for short bowel syndrome.